X4 Pharmaceuticals to Present and Participate in the Canaccord Genuity’s 40th Annual Growth Conference

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced management will present and hold one-on-one meetings at the Virtual Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 2:30 PM ET. A live webcast of the presentation will be accessible on the investor section of the X4 Pharmaceuticals website and archived for 90 days.

The firm specializes in therapies targeting CXCR4 pathway dysfunction, with its lead candidate, mavorixafor, being evaluated in multiple clinical trials for rare diseases and cancers.

CAMBRIDGE, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present and conduct one-on-one meetings during the Virtual Canaccord Genuity 40^th Annual Growth Conference on Wednesday, August 12^th, 2020 at 2:30 pm Eastern Time.

A live webcast of the presentation will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com. After the live webcasts, the events will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The Company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.  X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with Severe Congenital Neutropenia.  X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Cambridge, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: 
Candice Ellis, 857-341-1043 
Director, Corporate Communications & Investor Relations 
Candice.Ellis@x4pharma.com

FAQ

What is X4 Pharmaceuticals presenting at the Virtual Canaccord Genuity 40th Annual Growth Conference?

X4 Pharmaceuticals will present and hold one-on-one meetings on August 12, 2020, discussing their novel therapies targeting the CXCR4 pathway.

When will the X4 Pharmaceuticals presentation be available to watch?

The live webcast of X4 Pharmaceuticals' presentation will be available on their website on August 12, 2020, and archived for 90 days.

What is mavorixafor and its significance for X4 Pharmaceuticals?

Mavorixafor is X4 Pharmaceuticals' lead candidate, a first-in-class antagonist targeting CXCR4, currently in Phase 3 trials for WHIM syndrome and other diseases.

What types of clinical trials is X4 Pharmaceuticals conducting?

X4 Pharmaceuticals is conducting a global Phase 3 trial for WHIM syndrome and two Phase 1b trials for Waldenström’s macroglobulinemia and Severe Congenital Neutropenia.

Where are X4 Pharmaceuticals' headquarters and research facilities located?

X4 Pharmaceuticals is headquartered in Cambridge, Massachusetts, with a research facility in Vienna, Austria.